跳转至内容
Merck
CN

AB5206

Anti-Sodium Channel Antibody, Voltage Gated, Brain Type II

Chemicon®, from rabbit

别名:

Nav1.2, SCN2A

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IHC, WB
Citations:
12
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

rat, mouse

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable, western blot: suitable

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... SCN2A(6326)

General description

228 kDa

Immunogen

Purified peptide of alpha subunit (amino acids 467-485) of rat type II voltage-gated sodium channel (VGSC) (Accession P04775).

Application

All procedures that are going to receive a full-length protein should be performed at 4°C, and the following protease inhibitor mixture should be used: pepstatin A (1 μg/mL), leupeptin (1 μg/mL), aprotinin (1 μg/mL), Pefabloc SC (0.2 mM), benzamidine (0.1 mg/mL), and calpain inhibitors I and II (8 μg/mL each).

Western blot: 1:200 using ECL on rat brain membranes. Note: The addition of 2% Triton to the antibody is recommended for this lot number.

Immunohistochemistry on rat brain sections.

Dilutions should be made using a carrier protein such as BSA (1-3%)

Optimal working dilutions must be determined by the end user.
Anti-Sodium Channel Antibody, Voltage Gated, Brain Type II detects level of Sodium Channel & has been published & validated for use in IH & WB.
Research Category
Neuroscience
Research Sub Category
Ion Channels & Transporters

Biochem/physiol Actions

Recognizes type II alpha subunit of VGSC. Does not cross react with any other sodium channel antigens tested so far.

Physical form

Affinity Purified immunoglobulin. Lyophilized from phosphate buffered saline, pH 7.4, containing 1% BSA and 0.05% sodium azide as a preservative. Reconstitute with 200 μL of sterile deionized water. Centrifuge antibody preparation before use (10,000 xg for 5 min).
ImmunoAffinity Purified

Preparation Note

Maintain lyophilized material at -20°C for up to 12 months after date of receipt. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.

Analysis Note

Control
CONTROL ANTIGEN: Included free of charge with the antibody is 40 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of sterile deionized water. For negative control, preincubate 1 μg of peptide with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


hcodes

Hazard Classifications

Aquatic Chronic 3

存储类别

11 - Combustible Solids

wgk

WGK 3



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Voltage-gated sodium channels in taste bud cells.
Gao, N; Lu, M; Echeverri, F; Laita, B; Kalabat, D; Williams, ME; Hevezi, P; Zlotnik, A; Moyer, BD
BMC Neuroscience null
Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors.
Iwata, A; Stys, PK; Wolf, JA; Chen, XH; Taylor, AG; Meaney, DF; Smith, DH
The Journal of Neuroscience null
Benjamin Schattling et al.
JCI insight, 1(19), e89810-e89810 (2016-11-25)
Counteracting the progressive neurological disability caused by neuronal and axonal loss is the major unmet clinical need in multiple sclerosis therapy. However, the mechanisms underlying irreversible neuroaxonal degeneration in multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE) are



全球贸易项目编号

货号GTIN
AB520604053252324451
AB5206-50UL04053252335860